BOSUTINIB | BOSUTINIB | ATC L01XE14
ANTINEOPLASTIC TYROSINE KINASE INHIBITOR TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | ORAL | Cmax 0.37 MICROMOLAR VD 6080 LITER PPB 94 PERCENT Cl 189 LITER / HOUR HT 22.5 HOUR SOLUBILITY ABOVE PH 5 THE SOLUBILITY OF BOSUTINIB MONOHYDRATE REDUCES RAPIDLY | BCR-ABL PDB 4OTW (HER3 PSEUDOKINASE DOMAIN BOUND TO BOSUTINIB) LIGAND CODE = DB8 (link to the list of PDB complexes) Download experimental 3D coordinates of DB8 with added hydrogens | TYROSINE-PROTEIN KINASE ABL INHIBITOR CHEMBL1862 TYROSINE-PROTEIN KINASE ABL P00519 TYROSINE-PROTEIN KINASE ABL1 HOMO SAPIENS ENZYME KINASE PROTEIN KINASE TK ABL | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |